Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia

NCT02808442 is registered in ClinicalTrials.gov with Institut de Recherches Internationales Servier as lead sponsor.

NCT NCT02808442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02808442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia
Lead sponsor
Institut de Recherches Internationales Servier
Phase
Phase 1
Overall status
Completed
Start date
June 3, 2016
Completion date
November 4, 2020
Enrollment
13 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

refractory b-cell acute lymphoblastic leukemia, relapsed b-cell acute lymphoblastic leukemia